Enteric hyperoxaluria: An important cause of end-stage kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 375-382

  Nazzal, Lama ^a   Puri, Sonika ^a   Goldfarb, David S ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

inflammatory bowel disease; kidney stones; oxalate; transplantation; urolithiasis

Indexed keywords

ALLN 177; CALCIUM; CARBOXYLYASE; CITRIC ACID; COLESTYRAMINE; OXALIC ACID; OXALIC ACID DECARBOXYLASE; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AMINO ACID METABOLISM; CALCIUM OXALATE STONE; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIET SUPPLEMENTATION; ECHOGRAPHY; END STAGE RENAL DISEASE; ENTERIC HYPEROXALURIA; ENTEROPATHY; FEMALE; HEMODIALYSIS; HUMAN; HYPEROXALURIA; INTESTINE RESECTION; INTESTINE TRANSPLANTATION; KIDNEY CALCIFICATION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; MALE; MEDICAL HISTORY; MIDDLE AGED; NEPHROLITHIASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SURGICAL APPROACH; URETEROSCOPY; COMPLICATION; KIDNEY FAILURE, CHRONIC; UROLITHIASIS;

HUMANS; HYPEROXALURIA; KIDNEY FAILURE, CHRONIC; UROLITHIASIS;

EID: 84960154560     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv005     Document Type: Review

References (65)

1. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31: 927-949
2. Earnest DL. Enteric hyperoxaluria. Adv Intern Med 1979; 24: 407-427
3. Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13: 410-417
4. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54, e42; quiz e30
5. Nasr SH, D'Agati VD, Said SM, et al. Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008; 3: 1676-1683
6. Jungers P, Joly D, Barbey F, et al. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004; 44: 799-805
7. Alexander RT, Hemmelgarn BR, Wiebe N, et al. Kidney stones and kidney function loss: a cohort study. BMJ 2012; 345: e5287
8. Caudarella R, Rizzoli E, Pironi L, et al. Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 1993; 7: 371-379; discussion 379-380
9. Von Unruh GE, Voss S, Sauerbruch T, et al. Dependence of oxalate absorption on the daily calcium intake. J Am Soc Nephrol 2004; 15: 1567-1573
10. Robijn S, Hoppe B, Vervaet BA, et al. Hyperoxaluria: a gut-kidney axis? Kidney Int 2011; 80: 1146-1158
11. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59: 270-276
12. Hesse A, SchneebergerW, Engfeld S, et al. Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2] oxalate. J Am Soc Nephrol 1999; 10(Suppl 14): S329-S333
13. Hylander E, Jarnum S, Jensen HJ, et al. Enteric hyperoxaluria: dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol 1978; 13: 577-588
14. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol 2012; 8: 467-475
15. Bernhardt WM, Schefold JC, Weichert W, et al. Amelioration of anemia after kidney transplantation in severe secondary oxalosis. Clin Nephrol 2006; 65: 216-221
16. Sahin G, Acikalin MF, Yalcin AU. Erythropoietin resistance as a result of oxalosis in bone marrow. Clin Nephrol 2005; 63: 402-404
17. Blackmon JA, Jeffy BG, Malone JC, et al. Oxalosis involving the skin: case report and literature review. Arch Dermatol 2011; 147: 1302-1305
18. Gregoriou S, Kalapothakou K, Kontochristopoulos G, et al. Subungual oxalate deposits in a patient with secondary hyperoxaluria. Acta Derm Venereol 2011; 91: 195-196
19. Kiss D, Meier R, Gyr K, et al. Secondary oxalosis following small bowel resection with kidney insufficiency and oxalate vasculopathy. Schweiz Med Wochenschr 1992; 122: 854-857
20. Dobbins JW, Binder HJ. Importance of the colon in enteric hyperoxaluria. N Engl J Med 1977; 296: 298-301
21. Caspary WF, Tonissen J, Lankisch PG. 'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man. Acta Hepatogastroenterol (Stuttg) 1977; 24: 193-200
22. Hoyer-Kuhn H, Kohbrok S, Volland R, et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J AmSoc Nephrol 2014; 9: 468-477
23. Kumar R, Ghoshal UC, Singh G, et al. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation. J Gastroenterol Hepatol 2004; 19: 1403-1409
24. Kharlamb V, Schelker J, Francois F, et al. Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes. J Endourol 2011; 25: 1781-1785
25. Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol 2008; 28: 163-173
26. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752
27. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761
28. Agrawal V, Liu XJ, Campfield T, et al. Calcium oxalate supersaturation increases early after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2013; 10: 88-94
29. Canales BK, Ellen J, Khan SR, et al. Steatorrhea and hyperoxaluria occur after gastric bypass surgery in obese rats regardless of dietary fat or oxalate. J Urol 2013; 190: 1102-1109
30. O'Connor RC, Worcester EM, Evan AP, et al. Nephrolithiasis and nephrocalcinosis in rats with small bowel resection. Urol Res 2005; 33: 105-115
31. Matlaga BR, Shore AD, Magnuson T, et al. Effect of gastric bypass surgery on kidney stone disease. J Urol 2009; 181: 2573-2577
32. Semins MJ, Asplin JR, Steele K, et al. The effect of restrictive bariatric surgery on urinary stone risk factors. Urology 2010; 76: 826-829
33. Penniston KL, Kaplon DM, Gould JC, et al. Gastric band placement for obesity is not associated with increased urinary risk of urolithiasis compared to bypass. J Urol 2009; 182: 2340-2346
34. Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery 2011; 149: 654-661
35. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177: 565-569
36. Hueppelshaeuser R, Von Unruh GE, Habbig S, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol 2012; 27: 1103-1109
37. Drenick EJ, Stanley TM, Border WA, et al. Renal damage with intestinal bypass. Ann Intern Med 1978; 89: 594-599
38. Clayman RV, Williams RD. Oxalate urolithiasis following jejunoileal bypass. Surg Clin North Am 1979; 59: 1071-1077
39. Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72: 100-107
40. Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest 2013; 123: 236-246
41. Knauf F, Asplin JR, Granja I, et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 2013; 84: 895-901
42. Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol 2014; 3: 256-276
43. Hanna IR, Taniyama Y, Szocs K, et al. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 2002; 4: 899-914
44. Toblli JE, Ferder L, Stella I, et al. Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol 2002; 168: 1550-1555
45. Zuo J, Khan A, Glenton PA, et al. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol Dial Transplant 2011; 26: 1785-1796
46. Gambaro G, Ferraro PM, D'Addessi A. Ayurvedic medicine and NADPH oxidase: a possible approach to the prevention of ESRD in hyperoxaluria. Nephrol Dial Transplant 2011; 26: 1759-1761
47. Hylander E, Jarnum S, Nielsen K. Calcium treatment of enteric hyperoxaluria after jejunoileal bypass for morbid obesity. Scand J Gastroenterol 1980; 15: 349-352
48. Pang R, Linnes MP, O'Connor HM, et al. Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology 2012; 80: 250-254
49. Caspary WF. Intestinal oxalate absorption. I. Absorption in vitro. Res Exp Med (Berl) 1977; 171: 13-24
50. Nordenvall B, Backman L, Larsson L, et al. Effects of calcium, aluminium, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass. Acta Chir Scand 1983; 149: 93-98
51. Lindsjo M, Fellstrom B, Ljunghall S, et al. Treatment of enteric hyperoxaluria with calcium-containing organic marine hydrocolloid. Lancet 1989; 2: 701-704
52. Lieske JC, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. J Urol 2008; 179: 1407-1410
53. Pak CY, Fuller C, Sakhaee K, et al. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985; 134: 11-19
54. Koff SG, Paquette EL, Cullen J, et al. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology 2007; 69: 1013-1016
55. Lieske JC, Goldfarb DS, De Simone C, et al. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005; 68: 1244-1249
56. Grujic D, Salido EC, Shenoy BCet al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol 2009; 29: 86-93
57. Verani R, Nasir M, Foley R. Granulomatous interstitial nephritis after a jejunoileal bypass: an ultrastructural and histochemical study. Am J Nephrol 1989; 9: 51-55
58. Hassan I, Juncos LA, Milliner DS, et al. Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 2001; 76: 758-760
59. Ceulemans LJ, Nijs Y, Nuytens F, et al. Combined kidney and intestinal transplantation in patients with enteric hyperoxaluria secondary to short bowel syndrome. Am J Transplant 2013; 13: 1910-1914
60. Fairclough PD, Feest TG, Chadwick VS, et al. Effect of sodium chenodeoxycholate on oxalate absorption from the excluded human colon-A mechanism for 'enteric' hyperoxaluria. Gut 1977; 18: 240-244
61. Rankin AC, Walsh SB, Summers SA, et al. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant 2008; 8: 1755-1758
62. Cuvelier C, Goffin E, Cosyns JP, et al. Enteric hyperoxaluria: a hidden cause of early renal graft failure in two successive transplants: spontaneous late graft recovery. Am J Kidney Dis 2002; 40: E3
63. Tang X, Voskoboev NV, Wannarka SL, et al. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol 2014; 39: 376-382
64. Cossey LN, Rahim F, Larsen CP. Oxalate nephropathy and intravenous vitamin C. Am J Kidney Dis 2013; 61: 1032-1035
65. Illies F, Bonzel KE, Wingen AM, et al. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 2006; 70: 1642-1648